生物技术公司Adaptive Biotechnologies Corp（ADPT）今日盘后股价大幅上涨6.25%，引起了市场关注。
消息面上，公司于盘后交易时段前发布了最新的财务指引。一方面，公司预计其微小残留病（MRD）业务板块在2024财年的全年营收将达到2.55亿美元至2.65亿美元，显示了该核心业务强劲的增长预期。
另一方面，公司同时给出了全年运营开支（包含营收成本）的指引，预计将控制在3.5亿美元至3.6亿美元之间。市场分析认为，明确的营收增长前景与可控的成本预期相结合，增强了投资者对公司未来盈利能力的信心，从而推动了股价在盘后显著走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.